Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Gemcitabine + Cisplatin in 1st-line R/M NPC
NCT03707509Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Camrelizumab + Gem/Cis with Placebo + Gem/Cis (2 arms). Primary endpoint: Progression-Free Survival up to 24 month. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03707509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707509.